Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Eiger BioPharmaceuticals

NASDAQ EIGR
$0.0000 -2.05 -%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 20 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

-
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
15.76M
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.37
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
1.48M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-100.00 %

Upcoming events Eiger BioPharmaceuticals

All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart Eiger BioPharmaceuticals

Stock analysis Eiger BioPharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
- 25.03
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
- 3.57
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-0.22 9.56
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
-0.22 -0.17
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
518.49 7.67

Price change Eiger BioPharmaceuticals per year

6.20$ 13.49$
Min Max

Summary analysis Eiger BioPharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Eiger BioPharmaceuticals

Revenue and net income Eiger BioPharmaceuticals

All parameters

Stock news Eiger BioPharmaceuticals

All news
13 September 2023 в 18:00

Eiger BioPharmaceuticals Shares Hit New Lows After Scrapped Hepatitis D Study

13 September 2023 в 18:00

Eiger BioPharmaceuticals Shares Hit New Lows After Scrapped Hepatitis D Study

12 September 2023 в 23:55

Eiger BioPharmaceuticals to Discontinue Chronic Hepatitis Delta Study, Ends Licensing Talks

12 September 2023 в 23:50

Eiger BioPharmaceuticals to Discontinue Chronic Hepatitis Delta Study, Ends Licensing Talks

16 December 2022 в 02:15

Eiger BioPharmaceuticals Names David Apelian Interim CEO

16 December 2022 в 02:15

Eiger BioPharmaceuticals Names David Apelian Interim CEO

6 September 2022 в 17:20

Eiger BioPharmaceuticals Shares Slide After Status Report for Peginterferon Lambda

6 September 2022 в 17:20

Eiger BioPharmaceuticals Shares Slide After Status Report for Peginterferon Lambda

About company Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.
Address:
2155 Park Boulevard, Palo Alto, CA, United States, 94306
Company name: Eiger BioPharmaceuticals
Issuer ticker: EIGR
ISIN: US28249U1051
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2014-01-30
Sector: Healthcare
Industry: Biotechnology
Site: https://www.eigerbio.com

On which stock exchange are Eiger BioPharmaceuticals (EIGR) stocks traded?

Eiger BioPharmaceuticals (EIGR) stocks are traded on NASDAQ.

What is the ticker of Eiger BioPharmaceuticals stocks (EIGR)?

The stock ticker of Eiger BioPharmaceuticals’s stocks or in other words, the code is EIGR. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Eiger BioPharmaceuticals (EIGR) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Eiger BioPharmaceuticals (EIGR) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Eiger BioPharmaceuticals (EIGR) stocks traded?

Eiger BioPharmaceuticals (EIGR) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Eiger BioPharmaceuticals (EIGR) stocks today?

The current price of Eiger BioPharmaceuticals stocks on 05.05.2024 is 0 dollars. per share.

What is the dynamics of Eiger BioPharmaceuticals (EIGR) stocks from the beginning of the year?

Eiger BioPharmaceuticals (EIGR) quotes have increased by -100% from the beginning of the year up to 0 dollars. per 1 stocks.

How much did Eiger BioPharmaceuticals (EIGR) stocks increase in мае 2024?

This month Eiger BioPharmaceuticals (EIGR) quotes have increased by 0% to 0 dollars. per share.

How much are Eiger BioPharmaceuticals (EIGR) stocks worth?

Today, on October, 05.05.2024 Eiger BioPharmaceuticals’s (EIGR) stocks cost 0 dollars..

What is the market capitalization of Eiger BioPharmaceuticals (EIGR)?

Capitalization is the market value of Eiger BioPharmaceuticals (EIGR) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 05.05.2024, the market capitalization of Eiger BioPharmaceuticals (EIGR) is estimated at about 0 dollars.